Genetics Institute competitors

John Melo has 30 years of combined experience as an entrepreneur and thought leader in developing and growing technology companies and as a senior executive in the Oil & Gas industry. As President and Chief Executive Officer, Mr. Melo has led Amyris through successful technology development, industrial start up, product development and commercialization and a series of funding rounds, including the initial public offering. Before joining Amyris in 2007, Mr. Melo served in various senior executive positions at BP Plc (formerly British Petroleum) most recently as President of U.S. fuels operations where he successfully led a business transformation and significantly improved the financial performance. During his tenure at BP, Mr. Melo also served as Chief Information Officer of the refining and marketing segment; Senior Advisor for e-business strategy to Lord Browne, BP group chief executive; and Director of global brand development. In this last role, he helped develop the “Helios” re-branding effort. Before joining BP, Mr. Melo was with Ernst & Young. Mr. Melo currently serves on the board of directors of Renmatix Inc., serves on the board of directors of BayBio, serves on the Bio Industrial and Environmental section governing board, is a member of the Council for the Portuguese Diaspora and is a member of Young Presidents’ Organization (YPO). He was formerly an appointed member to the U.S. section of the U.S.-Brazil CEO Forum. When not working on the mission of making sustainable chemistry mainstream or championing the eradication of malaria, John enjoys skiing, reading and time with his family on the island of Pico in the Azores, his childhood home.

Mr. Enyedy joined ImmunoGen as President and Chief Executive Officer in 2016, bringing over twenty-five years of combined general management, business development, and legal experience in the biotechnology industry. Prior to ImmunoGen, he served as Executive Vice President and Head of Corporate Development for Shire plc leading the company’s Strategy, M&A, and Corporate Planning functions and providing commercial oversight for the company’s pre-Phase 3 portfolio. Previously, Mr. Enyedy served as CEO of Proteostasis Therapeutics, Inc., following 15 years at Genzyme Corporation in diverse roles, most recently as President of the Transplant, Oncology, and Multiple Sclerosis divisions. Before joining Genzyme, Mr. Enyedy was an associate with the law firm Palmer & Dodge. He holds a J.D. from Harvard Law School and a B.S. from Northeastern University. Mr. Enyedy also serves on the Board of Directors of Akebia Therapeutics, Inc. and The American Cancer Society of Eastern New England. He previously served on the Board of Directors of Fate Therapeutics, Inc. and Keryx Biopharmaceuticals, Inc.

Chief Executive Officer and member of the board of XOMA (NASDAQ: XOMA). Joined XOMA in 2009 and was appointed to the CEO role in late 2016. In early 2017, Mr. Neal led XOMA through a dramatic strategic pivot taking the company from a traditional R&D heavy biotech company and transforming it to a successful royalty monetization and aggregation company. In the years prior to becoming CEO of XOMA, he was instrumental in leading the company’s licensing and business development activities focused on maximizing the value of XOMA’s foundational antibody IP and knowhow. In addition to his role at XOMA, Mr. Neal currently serves as a Director at Leading Biosciences, a clinical stage biotech company based in Carlsbad, CA. Mr. Neal has more than twenty years of experience in the biotechnology industry encompassing roles in R&D, business development, financing and general management. Prior to XOMA, Mr. Neal was Acting Chief Executive Officer of Entelos Inc., a leading bio-simulation company that acquired Iconix Biosciences, a privately held company where Mr. Neal was Chief Executive Officer. At Iconix, Mr. Neal established multi-year collaborations with Bristol-Myers Squibb, Abbott Labs (now AbbVie), Eli Lilly and the U.S. Food and Drug Administration. From 1999-2002, he was Executive Vice President of Incyte Genomics, leading global commercial activities with pharmaceutical company collaborators and partners including Pfizer, Aventis, GSK and others. Earlier in his career, he was an executive with Monsanto Company in positions of increasing responsibility. Mr. Neal earned his B.S. in Biology and his M.S. in Genetics and Plant Breeding from the University of Manitoba, Canada, and holds an MBA degree from Washington University in St. Louis, MO.

Skip Wagner is a President and Chief Executive Officer at BioReliance and is based in College Station, Texas.

CR Ocean Engineering is a Samuel W. Croll, III, Chief Executive Officer of CR Ocean Engineering at Life Sciences - Search Solution Group.

Mark Leuchtenberger is a Board Member at Melinta Therapeutics Inc, Co-Founder at Alvos Therapeutics Inc, and Executive Chairman at Aleta Biotherapeutics and is based in Boston, Massachusetts. He has experience at Bain & Company and has worked as Board Member at Targanta Therapeutics; Chairman at XENETIC BIOSCIENCES, INC.; and Senior Officer at Biogen Idec. Mark works or has worked as BOARD MEMBER at Wake Forest University - WFU and Chairman at MassBio. He studied at Wake Forest University - WFU; Wake Forest University, Yale School of Management; and Yale School of Management between 1985 and 1987.